L3VLUP
ProSign in

BRKR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BRKRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BRKR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterBRKRVRTX
Q3 202010 holders, $2.2bn31 holders, $21.9bn
Q4 202010 holders, $3.0bn30 holders, $18.4bn
Q1 20218 holders, $3.6bn31 holders, $15.4bn
Q2 202114 holders, $4.3bn30 holders, $12.7bn
Q3 202118 holders, $4.2bn35 holders, $10.1bn
Q4 202115 holders, $4.1bn28 holders, $12.4bn
Q1 202213 holders, $3.0bn23 holders, $16.1bn
Q2 202214 holders, $2.9bn25 holders, $18.1bn
Q3 202214 holders, $1.7bn22 holders, $18.4bn
Q4 202210 holders, $2.0bn28 holders, $18.4bn
Q1 202312 holders, $2.1bn26 holders, $21.4bn
Q2 202312 holders, $2.0bn27 holders, $24.7bn
Q3 202311 holders, $1.4bn33 holders, $24.3bn
Q4 202313 holders, $1.7bn32 holders, $28.6bn
Q1 202410 holders, $2.1bn31 holders, $29.8bn
Q2 202410 holders, $1.7bn29 holders, $33.4bn
Q3 202410 holders, $1.8bn27 holders, $33.5bn
Q4 202412 holders, $1.4bn26 holders, $28.5bn
Q1 20259 holders, $817m21 holders, $35.4bn
Q2 20255 holders, $189m21 holders, $32.3bn
Q3 20257 holders, $123m22 holders, $25.9bn
Q4 20259 holders, $1.1bn26 holders, $31.8bn
Q1 20266 holders, $738m25 holders, $31.8bn
Q2 20269 holders, $1.8bn26 holders, $34.6bn
BRKR

Bruker Corp

Holders
13
Reported value
$1.7bn
Buyers
8
Sellers
6

Breadth +2 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BRKR (3)

ExodusPoint Capital Management LP, Holocene Advisors LP, Scion Asset Management LLC

Only VRTX (22)

Acadian Asset Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →